Spoor Johan M. bought 47,000 shares of Perspective Therapeutics, Inc. at $0.81 for $37.9k on Nov 11, 2026

Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
Chief Executive Officer
Chief Executive Officer
Filed Nov 12, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$37,943.10Shares × reported price
Shares traded
47,000Common Stock
Price per share
$0.81Reported price. Read footnotes for ranges.
% of reported position traded
79.15%This security and ownership context
Holdings after
106,383Direct
Trade date
Nov 11, 2026Buy
Filed
Nov 12, 2026, 8:30 AM ET1-day reporting delay
Accession
0001193125-26-457093Code P · Transaction 398247
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 59,383 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

CATX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CATX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 19, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago 0%1w ago 0%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8007 to $0.8157, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the transactions described in this footnote.